FDA Approves Clinical Testing of Minerva’s CAR T-cell Therapy for Metastatic BC
News
Minerva Biotechnologies will soon start the first human trials testing its investigational therapy huMNC2-CAR44, a CAR T-cell immunotherapy intended for breast cancer that has spread to other parts of the ... Read more